Carregant...

Concurrent Inhibition of NF-κB, Cyclooxygenase-2, and Epidermal Growth Factor Receptor Leads to Greater Anti-Tumor Activity in Pancreatic Cancer

Inactivation of survival pathways such as NF-κB, cyclooxygenase (COX-2), or epidermal growth factor receptor (EGFR) signaling individually may not be sufficient for the treatment of advanced pancreatic cancer (PC) as suggested by recent clinical trials. 3,3′-Diindolylmethane (B-DIM) is an inhibitor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ali, Shadan, Banerjee, Sanjeev, Schaffert, Jacqueline M., El-Rayes, Bassel F., Philip, Philip A., Sarkar, Fazlul H.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3093967/
https://ncbi.nlm.nih.gov/pubmed/20213764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcb.22523
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!